Global Neurological Disorder Drugs Market Projected to Surpass $114.65 Billion by 2029 with 6.2% Annual Growth

What Are the Market Size and Growth Forecast for the Neurological Disorder Drugs Market?
The market size for drugs targeting neurological disorders has seen robust growth in the past few years. The market, valued at $84.6 billion in 2024, is projected to reach $90.09 billion in 2025 with a compound annual growth rate (CAGR) of 6.5%. Factors such as promising results from animal testing, a surge in therapeutic treatment options, rising prevalence of neurological issues, governmental initiatives, and an increase in healthcare spending have significantly contributed to this historical growth.

In the coming years, the market for drugs treating neurological disorders is projected to expand significantly, reaching a value of $114.65 billion in 2029 with a compound annual growth rate (CAGR) of 6.2%. This predicted growth is due to several factors, including advancements in personalized treatment options, increased attention towards disease-altering therapies, broader application of digital biomarkers, and a rising incidence of neurological ailments. Future market trends are expected to feature drug design innovations, developments in neuroimaging and genetic research, as well as collaboration, licensing deals, and the rise of regenerative medicine.

What Are the Main Catalysts for Growth in the Neurological Disorder Drugs Market?
The surge in instances of neurologic illnesses is anticipated to drive the expansion of the market for neurologic disorder medications in the future. These disorders refer to ailments affecting the brain, nerves, and spinal cord due to structural, biochemical, or electrical irregularities, manifesting in numerous symptoms. This increase in neurological diseases is linked to the aging global population, and a heightened exposure to environmental, metabolic, and lifestyle risk factors. Drugs for neurological disorders serve a vital function in controlling these multifaceted conditions, providing symptom relief, decelerating disease progression, and enhancing patient's long-term outcomes. Example is a data from September 2024 by the Australian Institute of Health and Welfare, a government agency based in Australia. It forecasts that the demographic of people with dementia in Australia will more than double from 2023 to 2058, with numbers escalating from roughly 411,100 in 2023 to 849,300 by 2058. This population will include approximately 315,500 males and 533,800 females. Consequently, this upsurge in neurological disease instances is steering the growth of the neurologic disorder drugs market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

Which Key Market Leaders Are Driving Neurological Disorder Drugs Industry Growth?
Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

What Are the Emerging Trends in the Neurological Disorder Drugs Industry?
Primary companies within the neurological disorder drugs market are concentrating on the creation of advanced Ocrelizumab drug therapies. This is meant to bolster the effectiveness of treatments, enhance patient results, and broaden treatment alternatives for individuals with multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody and serves as a medicinal drug in managing multiple sclerosis (MS), a specific type of neurological disorder. For example, in February 2024, Roche Holding AG, a pharmaceutical entity based in Switzerland, introduced Ocrevus (Ocrelizumab) in India, classified as a novel disease-modifying therapy (DMT) drug for MS treatment. Ocrevus stands as the inaugural and solely authorized DMT for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS), backed by more than a decade of clinical and real-world data. It's a monoclonal antibody that specifically targets CD20-positive B cells, implicated in the autoimmune onslaught against the central nervous system initiated by MS. Suitable for treating both forms of MS-RRMS and PPMS, Ocrevus is the first-ever approved drug to do so. Administered intravenously, typically biannually, it has exhibited effectiveness in mitigating disease activity and hampering disability progression according to clinical trials.

What Are the Main Segments in the Neurological Disorder Drugs Market?
The neurological disorder drugs market covered in this report is segmented -

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes
2) By Indication: Epilepsy, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegtments:
1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine
2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists
3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics
4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic
5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Which Geographic Area Leads the Neurological Disorder Drugs Market?
North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Neurological Disorder Drugs Global Market Report?

- Market Size Analysis: Analyze the Neurological Disorder Drugs Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Neurological Disorder Drugs Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Neurological Disorder Drugs Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Neurological Disorder Drugs Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17207

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.